Key result
Malignancy in patients with Takotsubo syndrome was associated with increased long-term mortality compared to those without cancer.
Why the study?
Does the presence of malignancy increase long-term mortality in patients with Takotsubo syndrome?
Cohort (n=286)
Does the presence of malignancy increase long-term mortality in patients with Takotsubo syndrome?
Answers are grounded in this paper and cite their sources.
Malignancy is highly prevalent (20%) in patients with Takotsubo syndrome and serves as an independent predictor of increased long-term mortality.
Takotsubo syndrome (TTS) is an acute and transient myocardial dysfunction of the left and/or right ventricle. The acute presentation is indistinguishable from that of an acute coronary syndrome, whereas no culprit lesion responsible for the distinct wall motion abnormality can be found on coronary angiography.1 Growing evidence suggests that the long-term prognosis of TTS is much worse than expected.1 Non-cardiovascular events including cancer-related deaths contribute considerably to the increased mortality of TTS patients.2 Consequently, there is increasing speculation about a potential pathophysiological connection between cancer and TTS and some evidence that malignancies significantly influence the clinical course of TTS.3-5 The aim of this study was therefore to investigate the exact prevalence of malignancy and to assess its clinical consequences, including long-term survival, in a large cohort of TTS patients. A total of 286 TTS patients were included between February 2004 and April 2014. The diagnosis of TTS was confirmed using the revised Mayo Clinic criteria. The study was conducted in compliance with the Helsinki Declaration. Informed consent for the use of medical data for research purposes was obtained. The medical records of all patients were screened. Data were supplemented by telephone interviews to determine the prevalence of malignancy. Follow-up was also conducted using standardized telephone interviews. Statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). A two-sided P-value of ≤0.05 was considered to indicate statistical significance. Data were presented as the mean ± standard deviation (SD) for normally distributed continuous variables, the median (interquartile range) for non-normally distributed continuous variables, and as the number and percentage of patients for categorical variables. The comparison of categorical variables was performed using the χ2 test or Fisher's exact test in the context of low event rates. Continuous variables were assessed using the independent-samples t-test for normally distributed variables and the Wilcoxon rank-sum test for non-normally distributed variables. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were stated for outcome data. To visualize mortality, Kaplan–Meier plots were used. Mortality rates were compared using the log-rank test. Cox regression analysis was used to identify predictors of death during long-term follow-up. Of 286 TTS patients included in the study, follow-up data were available for 271 patients after a mean of 4.0 ± 2.5 years. The baseline clinical characteristics of the patient cohort are illustrated in Table 1. The prevalence of malignancy in this cohort was 20% (n = 56). Most patients had a pre-existing cancer diagnosis without any temporal link to the acute event of TTS (n = 53). Cancer was diagnosed after TTS in three patients (during the current hospital stay in one patient and at a later time in two patients). The most frequent types of malignancy were breast cancer (n = 11, 20%), colorectal cancer (n = 8, 14%), skin cancer (n = 7, 13%) and lung cancer (n = 5, 9%). There was no difference between the groups in 28-day (4% vs. 6%; HR 0.61, 95% CI 0.14–2.69; P = 0.51) and 1-year (11% vs. 13%; HR 0.82, 95% CI 0.34–1.97; P = 0.65) mortality. Long-term mortality was significantly increased in TTS patients with malignancies (39% vs. 21%; HR 1.67, 95% CI 1.00–2.80; P = 0.05) (Figure 1). Patients with TTS and cancer were more frequently affected by non-cardiovascular death (30% vs. 5%; HR 5.71, 95% CI 2.59–12.59; P < 0.001). There was no significant difference in terms of cardiovascular or unknown cause of death. In Cox regression analysis, the presence of malignancy was a predictor of mortality (multivariable analysis: HR 2.17, 95% CI 1.23–3.84; P = 0.008). Using the results of the EUROPREVAL study, which investigated prevalences of different types of malignant neoplasia in 17 European countries,6 the prevalence of cancer in the present TTS population was approximately twice as high as that in the same age group in Germany (20% vs. 11%) and in the whole of Europe (20% vs. 7.8%). However, the frequency distribution of the detected tumour types corresponded to the expected distribution in the same age group of the normal population.6 This study is the largest systematic assessment of exact prevalences and the clinical impact of malignancies in patients with TTS to date. The first systematic trial to investigate the concomitance of TTS and malignancies was conducted by Burgdorf et al. and showed that the prevalence of malignancy in TTS patients was higher than that in a matched group of patients with myocardial infarction (18% vs. 6%).5 Very recently, two studies found cancer prevalences among TTS patients of 28.5%3 and 21.9%,4 respectively. These results are in line with the prevalence of malignancy observed in the current study (20%), which is substantially higher than in an age-matched normal population.6 The reasons for the high prevalence of malignancy remain speculative. Given the time gap between cancer diagnosis and the occurrence of TTS, it is doubtful that the cancer diagnosis acutely triggered TTS. It is rather more conceivable that cancer and TTS share similar triggering mechanisms. Activation of the sympathetic nervous system may be a trigger for malignancies, as well as for TTS. For instance, high catecholamine levels have been shown to lead to increased growth of several malignant tumours.7 Furthermore, a genetic background is imaginable. For instance, alterations in the gene for BAG3 (bcl2-associated athanogene 3) are held responsible for the occurrence of cancer,8 as well as for that of TTS.8 Although current knowledge of the underlying pathomechanisms still leaves room for further interpretation and speculation, there is no doubt about the clinical consequences of concurrent TTS and cancer. The overall long-term mortality of TTS patients with malignant disease is significantly increased. Additionally, in concordance with previous data, cancer was identified as an independent predictor for mortality in multivariable Cox regression analysis.3, 4 Therefore, TTS patients with cancer should be considered a high-risk subgroup with respect to their increased mortality rate. Whether and to what extent these results should lead to a generalized cancer screening in TTS patients must be determined in future studies. The prevalence of malignancy in patients with TTS is high and considerably exceeds that in the normal population. Furthermore, malignant tumours are major determinants of long-term mortality in TTS. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Möller et al. (2017) conducted a cohort in Takotsubo syndrome (n=286). Malignancy vs. No malignancy was evaluated on Long-term mortality (HR 1.67, 95% CI 1.00-2.80, p=0.05). Malignancy in patients with Takotsubo syndrome was associated with increased long-term mortality compared to those without cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: